You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光(600673.SH):東陽光藥獲磷酸依米他韋膠囊藥品註冊證書
格隆匯 12-28 16:51

格隆匯12月28日丨東陽光(600673.SH)公佈,公司控股子公司宜昌東陽光長江藥業股份有限公司(以下簡稱“東陽光藥”)於近日收到國家藥監局核准簽發的《藥品註冊證書》。

磷酸依米他韋是口服直接抗丙肝病毒藥物,非結構蛋白(“NS”)5A抑制劑。該藥品針對基因1型無肝硬化丙肝患者療效顯著,12周持續病毒應答率(SVR12)達99.8%,且用藥安全性及耐受性良好。磷酸依米他韋膠囊為東陽光藥的獨家產品。

磷酸依米他韋膠囊是中國1類創新藥,根據艾美仕數據顯示,2019年國內口服抗丙肝病毒藥物銷售金額為1300多萬美元,較2018年增長率為75.3%,具有可觀的增長潛力。

本次獲批產品具有很高的臨牀應用價值和良好的市場前景,上市後將成為東陽光藥在抗丙肝治療領域的主打產品之一,有利於拓展公司抗病毒領域業務,進一步豐富公司的產品組合,為廣大患者提供質價雙優的用藥選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account